The onset of effect for escitalopram and its relevance for the clinical management of depression

Authors: Wade, Alan1; Friis Andersen, Henning2

Source: Current Medical Research and Opinion, Volume 22, Number 11, November 2006 , pp. 2101-2110(10)

Publisher: Informa Healthcare

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Objective: To analyse the significance of 'onset of effect' on clinical outcome in the treatment of depression and the contribution of individual Montgomery-Åsberg Depression Rating Scale (MADRS) items to improvements in the MADRS total score.

Research design and method: All five published placebo-controlled clinical studies in depression as per January 1, 2005, with escitalopram, were included in this pooled analysis.

Results: Of the 1636 patients who were randomised to either escitalopram (882) or placebo (754), 1333 completed 8 weeks of treatment (707 escitalopram and 626 placebo). A statistically significant difference (p < 0.05) between the MADRS total score responses of escitalopram and placebo treatments was observed at week 1. All 10 MADRS single items showed a significant treatment effect at week 8. For items representing core symptoms of depression (apparent sadness, reported sadness, inner tension, concentration difficulties, inability to feel, pessimistic thoughts and suicidal thoughts) the effect was detected early (week 1) and for other items (reduced sleep, reduced appetite and lassitude) the effect was detected later (week 6-8). Of the patients who showed an onset of effect (≥ 20% reduction in MADRS) after 2 weeks, and who remained on escitalopram until week 8, 63% were in remission at week 8 (mean MADRS score of 6.1).

Conclusion: Onset of treatment response at 2 weeks is an important indicator of subsequent remission at 8 weeks. It would therefore be a reasonable clinical recommendation that if patients fail to show a measurable clinical improvement within 2 weeks, a dose increase should be considered at this time.

Keywords: DEPRESSION; ESCITALOPRAM; MADRS; MAJOR DEPRESSION; ONSET; REMISSION; SINGLE ITEMS

Document Type: Research article

DOI: 10.1185/030079906X148319

Affiliations: 1: CPS Clinical Research Centre, Glasgow, UK 2: Department of Biostatistics, H. Lundbeck A/S, Valby, Denmark

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$51.50 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A